PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsEnoxaparin
Enoxaparin sodium
Enoxaparin, Inhixa, Lovenox (enoxaparin sodium) is an oligosaccharide pharmaceutical. Enoxaparin sodium was first approved as Lovenox (preservative free) on 1993-03-29. It is used to treat myocardial infarction, postoperative complications, pulmonary embolism, thromboembolism, and thrombophlebitis amongst others in the USA. It has been approved in Europe to treat venous thromboembolism. The pharmaceutical is active against antithrombin-III.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
respiratory tract diseasesD012140
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Enoxaparin, Lovenox (discontinued: Lovenox)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Enoxaparin sodium
Tradename
Company
Number
Date
Products
LOVENOX (PRESERVATIVE FREE)SanofiN-020164 RX1993-03-29
7 products, RLD
LOVENOXSanofiN-020164 RX2003-01-23
1 products, RLD
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
enoxaparin sodiumANDA2024-10-14
enoxaparin sodium injection,uspANDA2024-08-05
enoxiluv kitunapproved drug other2024-10-05
lovenoxNew Drug Application2024-05-31
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
B: Blood and blood forming organ drugs
B01: Antithrombotic agents
B01A: Antithrombotic agents
B01AB: Heparin group antithrombotic drugs
B01AB05: Enoxaparin
HCPCS
Code
Description
J1650
Injection, enoxaparin sodium, 10 mg
Clinical
Clinical Trials
454 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ThromboembolismD013923HP_0001907540482728139
Venous thromboembolismD054556EFO_0004286I74534432021114
ThrombosisD013927723282528105
Venous thrombosisD020246HP_0004936I82.4062020211880
Covid-19D00008638231519111255
Pulmonary embolismD011655HP_0002204I26681591045
EmbolismD004617461510941
Myocardial infarctionD009203EFO_0000612I211107421
InfarctionD007238EFO_00094631107421
HemorrhageD006470MP_0001914R58115916
Show 68 more
Indications Phases 3
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LymphomaD008223C85.91213
Ovarian neoplasmsD010051EFO_0003893C5633
Morbid obesityD009767EFO_00010742113
Pregnancy rateD0188731113
Spinal cord injuriesD013119EFO_1001919112
Type 1 diabetes mellitusD003922EFO_0001359E10112
Plasma cell neoplasmsD05421922
Intracranial thrombosisD020767122
Ovarian epithelial carcinomaD00007721622
Plastic surgery proceduresD01965122
Show 23 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Fetal deathD005313HP_0003826224
Cesarean sectionD00258511
Systemic lupus erythematosusD008180HP_0002725M3211
Disease progressionD01845011
Indications Without Phase
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameEnoxaparin sodium
INNenoxaparin sodium
Description
Enoxaparin sodium, sold under the brand name Lovenox among others, is an anticoagulant medication (blood thinner). It is used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) including during pregnancy and following certain types of surgery. It is also used in those with acute coronary syndrome (ACS) and heart attacks. It is given by injection just under the skin or into a vein. It is also used during hemodialysis.
Classification
Oligosaccharide
Drug classheparin derivatives and low molecular weight (or depolymerized) heparins
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID679809-58-6
RxCUI
ChEMBL IDCHEMBL1201476
ChEBI ID
PubChem CID772
DrugBankDB01225
UNII ID8NZ41MIK1O (ChemIDplus, GSRS)
Target
Agency Approved
SERPINC1
SERPINC1
Organism
Homo sapiens
Gene name
SERPINC1
Gene synonyms
AT3
NCBI Gene ID
Protein name
antithrombin-III
Protein synonyms
serine (or cysteine) proteinase inhibitor, clade C (antithrombin), member 1, Serpin C1, serpin peptidase inhibitor clade C member 1, serpin peptidase inhibitor, clade C (antithrombin), member 1
Uniprot ID
Mouse ortholog
Serpinc1 (11905)
antithrombin-III (P32261)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
£
Lovenox Sanofi
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Enoxaparin sodium
+
Enoxaparin
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 22,523 documents
View more details
Safety
Black-box Warning
Black-box warning for: Enoxaparin sodium, Enoxaparin sodium injection,usp, Enoxiluv kit, Lovenox
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
34,776 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use